Ever since the 2018 Farm Bill legalized the cultivation and sale of industrial hemp and its derivatives, the demand for cannabidiol (“CBD”), a hemp extract claimed to be full of potent medicinal properties, has skyrocketed. Plenty of people around the country have been using CBD to alleviate a wide variety of health issues including pain, anxiety, and skin conditions such as acne and psoriasis, among others. As the nascent CBD industry grows every year, scientists around the world have been avidly studying the cannabinoid to see just how much medical potential it holds.
A recent study by researchers from Sichuan University’s West China Hospital of Stomatology has revealed that thanks to its potent anti-inflammatory properties, CBD may be able to alleviate the pain associated with oral ulcers as well as increase the rate of healing. Presented at the 99th General Session & Exhibition of the International Association for Dental Research, the study utilized mouse models depicting oral ulcers created by mechanical trauma or acid etching in the mouths of the laboratory mice.
After the researchers applied an oral spray containing CBD and ran histological and macroscopic evaluations, they found that cannabidiol was quite capable of treating the pain triggered by the inflammation caused by the ulcers. Applying the cannabidiol oral spray topically to the ulcers in a dose-dependent way resulted in faster wound closure and eliminated the possibility of weight loss.
Xingying Qi, the lead study author says the application of a cannabidiol oral spray led to a significant reduction in inflammation and pain, as well as expedited lesion closure. Although oral ulcers are a common oral inflammatory lesion that can cause severe pain, few effective treatment options are available. The results of this Chinese study indicate that cannabidiol represents a potential treatment for oral ulcers.
Curious to see how CBD alleviated oral ulcer symptoms, the researchers delved even deeper. After analyzing published datasets showing RNA-sequences linked to recurrent aphthous ulcers, they found that high NLPR3 expression, which plays a major role in inflammation and the body’s immune system, was a likely contributory factor in the onset of recurrent aphthous ulcers. Their research revealed that “cannabidiol significantly deactivates NLRP3 inflammasome expression” and may inhibit inflammasome-related pyroptosis, making it quite helpful in oral ulcer treatment.
The researchers also noted that cannabidiol reduced the activation of CMPK2, an enzyme that controls mitochondrial DNA synthesis, in turn reducing the synthesis of new mitochondrial DNA and suppressing the activation of inflammasome. The results of the Sichuan University study were published in the “Journal of Dental Research.”
There is much yet to be known about the therapeutic properties of CBD, but the fact that many companies, including Simply Sonoma Inc., are thriving as manufacturers of CBD medicinals means that consumers may intuitively be aware of the numerous benefits such protects have.
NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.